![Terry Tenbrunsel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Terry Tenbrunsel
Vendite & Marketing presso Bayer HealthCare Pharmaceuticals, Inc.
Provenienza dei contatti di primo grado di Terry Tenbrunsel
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Bayer HealthCare Pharmaceuticals, Inc.
![]() Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Bayer HealthCare Pharmaceuticals, Inc. manufactures pharmaceutical drugs. It offers pharmaceuticals and therapeutics in the areas of diagnostic imaging, hematology and cardiology, cancer, women's health and several other chronic diseases such as multiple sclerosis and Parkinson's disease. Bayer HealthCare Pharmaceuticals was founded in 1979 and is located in Wayne, NJ.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Terry Tenbrunsel tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
SillaJen Biotherapeutics, Inc.
![]() SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Actimed Therapeutics Ltd.
![]() Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Kalivir Immunotherapeutics, Inc.
![]() Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | Pharmaceuticals: Major | Director/Board Member | |
Coagulant Therapeutics, Inc.
![]() Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Pharmaceuticals: Major | Founder |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Regno Unito | 2 |
Settori
Health Technology | 4 |
Commercial Services | 3 |
Posizioni
Director/Board Member | 5 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 1 |
Founder | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Contatti più connessi
Insiders | |
---|---|
Terry Hermiston | 5 |
Frank Misselwitz | 2 |
Michael Devoy | 1 |
- Borsa valori
- Insiders
- Terry Tenbrunsel
- Connessioni Società